Covaxin shots ‘effective’ against new UK strain

Tribune Web Desk

Updated At : 12:14 PM Jan 28, 2021 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

New Delhi, January 27

Made-in-India Covaxin works against the Covid strain circulating in India as well as the new UK mutant, a research has shown.

The landmark peer-reviewed research by ICMR scientists shows the mutant will not escape the grip of ICMR-Bharat Biotech made Covaxin, currently being used in the national Covid vaccination drive.

“This dispels all uncertainties around whether or not Covaxin will work if the virus mutates,” says the research. Sera collected from Covaxin recipients neutralised the UK variants, the scientists say.

“The UK variant of the Sars-Cov2 with all its signature mutations was isolated and cultured in the world successfully for the first time at ICMR’s lab National Institute of Virology, Pune,” ICMR chief Balram Bhargava said. — TNS

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles